Published in Mol Metab on May 01, 2015
Cell Models and Their Application for Studying Adipogenic Differentiation in Relation to Obesity: A Review. Int J Mol Sci (2016) 0.83
Muscle mitochondrial stress adaptation operates independently of endogenous FGF21 action. Mol Metab (2015) 0.79
FGF21 Is Associated with Acanthosis Nigricans in Obese Patients. Int J Endocrinol (2016) 0.78
Implication of hepatokines in metabolic disorders and cardiovascular diseases. BBA Clin (2016) 0.77
Patterns of Circulating Fibroblast Growth Factor 21 in Subjects with and without Type 2 Diabetes. PLoS One (2015) 0.75
Single ingestion of soy β-conglycinin induces increased postprandial circulating FGF21 levels exerting beneficial health effects. Sci Rep (2016) 0.75
Nuclear factor E2-related factor 2 knockdown enhances glucose uptake and alters glucose metabolism in AML12 hepatocytes. Exp Biol Med (Maywood) (2017) 0.75
Inter-organ regulation of adipose tissue browning. Cell Mol Life Sci (2016) 0.75
FGF-21 as a novel metabolic regulator. J Clin Invest (2005) 10.69
Identification and characterization of metabolically benign obesity in humans. Arch Intern Med (2008) 5.74
FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev (2012) 5.71
Fibroblast growth factor 21 corrects obesity in mice. Endocrinology (2008) 5.66
PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes (2001) 5.18
Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. Histochemistry (1992) 4.63
Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes (2008) 4.50
Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology (2009) 3.10
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab (2013) 3.09
CARMAweb: comprehensive R- and bioconductor-based web service for microarray data analysis. Nucleic Acids Res (2006) 2.93
Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology (2002) 2.72
Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol (2010) 2.65
Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology (2010) 2.50
FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity. FEBS Lett (2008) 2.42
Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci U S A (2010) 2.27
Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care (2009) 2.15
Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun (2003) 1.82
Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab (2008) 1.68
Circulating fibroblast growth factors as metabolic regulators--a critical appraisal. Cell Metab (2012) 1.67
Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol (2013) 1.53
The metabolically benign and malignant fatty liver. Diabetes (2011) 1.39
Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes Metab Res Rev (2011) 1.30
Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab (2012) 1.15
Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS One (2013) 1.15
Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: the Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab (2012) 1.09
Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur J Endocrinol (2012) 1.09
High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator. Obes Res (2004) 1.09
Evidence for a local renin angiotensin system in primary cultured human preadipocytes. Int J Obes Relat Metab Disord (1999) 1.05
Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage. J Clin Endocrinol Metab (2013) 1.04
Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol (2013) 1.01
Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: relationship with plasma FGF21 and body adiposity. Diabetes (2011) 1.01
Corticosteroid-dependent differentiation of human marrow preadipocytes in vitro. In Vitro (1979) 1.00
Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care (2012) 1.00
Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels. Eur J Endocrinol (2010) 0.97
Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance. PLoS One (2012) 0.93
Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects. Obesity (Silver Spring) (2013) 0.89
Adiponectin: an adipokine linking adipocytes and type 2 diabetes in humans. Curr Diab Rep (2005) 0.88
Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clin Endocrinol (Oxf) (2013) 0.86
Metabolic signatures of cultured human adipocytes from metabolically healthy versus unhealthy obese individuals. PLoS One (2014) 0.85
Cardiorespiratory fitness and visceral fat are key determinants of serum fibroblast growth factor 21 concentration in Japanese men. J Clin Endocrinol Metab (2014) 0.84
Serum FGF21 increases with hepatic fat accumulation in pediatric onset intestinal failure. J Hepatol (2013) 0.82
Evaluation of total adiponectin, adipocyte fatty acid binding protein and fibroblast growth factor 21 levels in individuals with metabolic syndrome. Physiol Res (2014) 0.79
Adiponectin isoforms differentially affect gene expression and the lipidome of primary human hepatocytes. Metabolites (2014) 0.79